Utility and Performance of Heart Transplant Test Confirmed
|
By LabMedica International staff writers Posted on 24 Jun 2015 |
|
Image: Histopathology of interstitial edema in a cardiac transplant biopsy may be a sign of antibody-mediated rejection (Photo courtesy of the Society for Cardiovascular Pathology).
An innovative molecular blood test has been used following a heart transplant procedure and this test enables routine, noninvasive surveillance of acute cellular rejection, thereby assisting clinicians in the care and management of patients.
New uses of the test have been described, specifically, the combination of the test with the measure of donor-specific cell-free DNA which improves the performance of the test, or an analysis of correlations between test scores and long-term outcome for patients, which could give a new predictive role to the test.
In the Cardiac Allograft Rejection Gene Expression Observational II (CARGO II) prospective, observational, multicenter clinical study blood samples for testing were collected during post-transplant surveillance visits, beginning at least 55 days after heart transplantation, with or without cardiac biopsy. After analyzing the samples, the test result was provided as a unique score ranging from 0 to 40, with high values indicating a greater risk of acute cellular rejection.
Moderate to severe acute cellular rejection (i.e., histopathology analysis of biopsies showing a grade greater than or equal to 3A according to the International Society for Heart and Lung Transplantation grading system) were reported by pathologists in 106 out of 3,324 biopsies (3.2%), in 79 out of 594 patients (13.0%). Taking into account these observations, the study shows that the negative predictive value of AlloMap (DIAXONHIT; Paris, France) is greater or equal to 99.0% for AlloMap scores less than 34. This threshold is therefore associated with a low risk of moderate to severe acute cellular heart graft rejection.
Loïc Maurel, MD, President of the Management Board of DIAXONHIT, said, “With a central laboratory becoming operational soon in Strasbourg, France, DIAXONHIT will be able to duplicate the testing practice already conducted by CareDx (Brisbane, CA, USA) in the US, and provide AlloMap testing to European patients for whom the performance of the test was confirmed in the CARGO II study. The results that were presented during the second joint symposium at this year’s International Society for Heart and Lung Transplantation congress organized by DIAXONHIT and CareDx are quite encouraging, as they confirm a more routine use of the test in several US centers and already present potential new uses of AlloMap that should further benefit heart transplant patients.”
Related Links:
DIAXONHIT
CareDx
New uses of the test have been described, specifically, the combination of the test with the measure of donor-specific cell-free DNA which improves the performance of the test, or an analysis of correlations between test scores and long-term outcome for patients, which could give a new predictive role to the test.
In the Cardiac Allograft Rejection Gene Expression Observational II (CARGO II) prospective, observational, multicenter clinical study blood samples for testing were collected during post-transplant surveillance visits, beginning at least 55 days after heart transplantation, with or without cardiac biopsy. After analyzing the samples, the test result was provided as a unique score ranging from 0 to 40, with high values indicating a greater risk of acute cellular rejection.
Moderate to severe acute cellular rejection (i.e., histopathology analysis of biopsies showing a grade greater than or equal to 3A according to the International Society for Heart and Lung Transplantation grading system) were reported by pathologists in 106 out of 3,324 biopsies (3.2%), in 79 out of 594 patients (13.0%). Taking into account these observations, the study shows that the negative predictive value of AlloMap (DIAXONHIT; Paris, France) is greater or equal to 99.0% for AlloMap scores less than 34. This threshold is therefore associated with a low risk of moderate to severe acute cellular heart graft rejection.
Loïc Maurel, MD, President of the Management Board of DIAXONHIT, said, “With a central laboratory becoming operational soon in Strasbourg, France, DIAXONHIT will be able to duplicate the testing practice already conducted by CareDx (Brisbane, CA, USA) in the US, and provide AlloMap testing to European patients for whom the performance of the test was confirmed in the CARGO II study. The results that were presented during the second joint symposium at this year’s International Society for Heart and Lung Transplantation congress organized by DIAXONHIT and CareDx are quite encouraging, as they confirm a more routine use of the test in several US centers and already present potential new uses of AlloMap that should further benefit heart transplant patients.”
Related Links:
DIAXONHIT
CareDx
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Auto Clinical Chemistry Analyzer
cobas c 703
Latest Molecular Diagnostics News
- Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
- Novel Autoantibody Against DAGLA Discovered in Cerebellitis
- Blood Test Could Identify Patients at Risk for Severe Scleroderma
- Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
- Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease
- Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy
- RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
- First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
- Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
- Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
- Blood Test Rules Out Future Dementia Risk
- D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
- New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
- Chemiluminescence Immunoassays Support Diagnosis of Alzheimer’s Disease
- Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury
- Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
